A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Phase 3
330
about 3.9 years
18–99
35 sites in AR, AZ, CA +18
What this study is about
Researchers are testing whether tarlatamab added to durvalumab, carboplatin, and etoposide prolongs survival compared to durvalumab, carboplatin, and etoposide alone in people with extensive stage small cell lung cancer. The trial will last for about 1427 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Durvalumab
- 3.Take Etoposide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, durvalumab, etoposide, tarlatamab
infusion, injection, intravenous
Primary: Overall Survival (OS), Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)
Secondary: Disease Control, Duration of Response (DOR), Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs), Number of Participants Who Experience Treatment-related Adverse Events, OS Rate, Objective Response (OR), PFS (Investigator Assessed), PFS Rate
Oncology